Norwood Abbey Highlights Needle-Free Drug Delivery System and Commercial Strategic Update
May 09 2006 - 11:53AM
Business Wire
Norwood Abbey Ltd (ASX:NAL): Key points: -- Needle-free delivery -
objective of the global pharmaceutical industry -- Norwood
needle-free prototype developed at MIT -- Commercial phase licence
with MIT in place -- Multiple approaches to Norwood/MIT from
pharmaceutical groups -- Commercial discussions underway -- Norwood
device specifications address market needs Norwood Abbey Ltd
(ASX:NAL) states that the compelling drivers for a needle-free drug
delivery system are the provision of an efficacious means of
delivering compounds to humans and animals in a safe and
cost-effective manner. Avoiding cross-contamination through
needlestick injury has long been a significant health concern with
the current syringe method of delivery. Needle-free drug delivery
has been a key objective of the global pharmaceutical industry for
over a decade. Many variant designs and delivery mechanisms have
been researched by numerous companies with mixed results. No one
has brought to market a needle-free device that is effective across
the broad range of delivery applications for which the industry
seeks solutions. Norwood Abbey Ltd has, through its research
agreement with the Massachusetts Institute of Technology (MIT) -
BioInstrumentation Laboratory, spent the past three years
perfecting a unique method of needle-free drug delivery. Following
an extensive research program, Norwood has now entered into a
commercial phase licence with MIT under which Norwood has the
exclusive global rights to exploit the intellectual property and
know-how held by MIT in the field. Norwood is now progressing its
previously announced strategy of partnering/licensing the
needle-free technology with major pharmaceutical groups. The
proposed partnering/licensing model envisages the offering of
exclusive licences for specific applications. Thus, one
pharmaceutical company might licence the rights in relation to a
particular arthritis drug, another for an anti-inflammatory drug
and another for an influenza vaccine. Norwood seeks to develop a
portfolio of licensing arrangements where each licensee has a
unique offering linking its drug to the Norwood delivery system.
Norwood is now in a strong position to create a portfolio of
licensing arrangements with major pharmaceutical groups. Norwood
has now commenced commercial discussions with a number of
pharmaceutical groups who have approached Norwood (both directly
and through MIT). The Norwood prototype device has been designed to
meet the specifications nominated by selected pharmaceutical groups
and to address key issues that have limited the commercial
development of other companies' devices. Important features of the
Norwood device are: -- Re-usable hand-held device with powerful
(patented) delivery mechanism -- Concept of a single-use disposable
drug cartridge -- Safe and efficacious delivery method -- Near
silent operation -- Low per procedure cost -- Control of 'force'
enabling delivery to controlled depth -- Ability to deliver a wide
range of drugs or biologicals -- Optimum size expected to
approximate small hand-held drill -- Both human and veterinary
models To find out more about the company, visit
www.norwoodabbey.com
Norwood Abbey (ASX:NAL)
Historical Stock Chart
From May 2024 to Jun 2024
Norwood Abbey (ASX:NAL)
Historical Stock Chart
From Jun 2023 to Jun 2024